Pacira Pharmaceuticals to acquire Myoscience for up to $220M — 5 insights

Pacira Pharmaceuticals will acquire Myoscience, a targeted pain therapies company, for up to $220 million, AP News reports.

What you should know:

1. The transaction is expected to close by April.

2. Pacira's payment will include $120 million in cash up front and an additional $100 million upon achievement of commercial and regulatory milestones.

3. Under the agreement, Myoscience's iovera will become part of Pacira's portfolio.

4. Iovera freezes peripheral nerves through cryoneurolysis for opioid-free pain relief.

5. Last year, CMS approved separate payments to ASCs that use Pacira's non-opioid pain management drug, Exparel.

More articles on supply chain:
SurgCenter Development forms 200th ASC partnership — Company in 'full-growth mode'
Illinois community may benefit from ASC, OSF Regional Vice President says — 3 insights
How Southern California Orthopedic Institute shifted total joints to ASCs using bundled payments — 5 insights

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers